2025-12-19 - Analysis Report
Okay, here's a breakdown of the provided data for Procter & Gamble (PG), aiming for clarity and simplicity first, followed by analysis:

**1. Return Rate vs. S&P 500 (VOO)**

*   **Company Overview:** Procter & Gamble Co. is a multinational consumer goods corporation that provides a wide range of branded consumer packaged goods.
*   **PG Cumulative Return:** 27.06%
*   **VOO (S&P 500) Cumulative Return:** 99.09%
*   **Divergence:** -73.0 (Relative Divergence: 7.0)

**Analysis:** PG has significantly underperformed the S&P 500 over the analyzed period. The divergence of -73% indicates a substantial difference in cumulative returns. The relative divergence of 7.0 suggests that this level of underperformance is near the lower end of its historical range relative to the S&P 500, implying that while the divergence is large, it's not unprecedented.

**Alpha, Beta Analysis**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 21.0% | 7.9% | -8.0% | 0.0 | 215.0 |
| 2016-2018  | 9.0% | 67.3% | -6.0% | 0.1 | 215.1 |
| 2017-2019  | 24.0% | 70.4% | 2.0% | 0.3 | 292.3 |
| 2018-2020  | 27.0% | 78.8% | 4.0% | 0.4 | 325.7 |
| 2019-2021  | 41.0% | 78.8% | -5.0% | 0.5 | 382.9 |
| 2020-2022  | 13.0% | 79.4% | 13.0% | 0.6 | 354.7 |
| 2021-2023  | 26.0% | 79.4% | 24.0% | 0.4 | 343.0 |
| 2022-2024  | 9.0% | 79.4% | -12.0% | 0.4 | 392.4 |
| 2023-2025  | -17.0% | 80.1% | -81.0% | 0.1 | 340.6 |

**Analysis:**

* **CAGR:** Fluctuating, with the recent period (2023-2025) showing a significant negative return.
* **MDD:**  Maximum Drawdown has generally increased over time, suggesting higher risk.
* **Alpha:** Alpha, which represents the excess return compared to the benchmark, has varied. Note the significantly negative Alpha in the most recent period (2023-2025), indicating severe underperformance.
* **Beta:** Beta values are consistently low, suggesting PG is less sensitive to overall market movements.
* **Cap:** Market capitalization has fluctuated, showing growth followed by a recent decline.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 145.52
*   **Previous Close:** 147.81
*   **Change:** -1.55
*   **5-day SMA:** 145.30
*   **20-day SMA:** 145.09
*   **60-day SMA:** 148.19

**Analysis:** The stock price has recently declined (negative change). The 5-day and 20-day SMAs are close, indicating short-term price stability. The 60-day SMA is higher than the current price, suggesting a recent downtrend.

**3. Technical Indicators**

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment Recommended)
*   **RSI:** 44.40
*   **PPO:** 0.36
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (7 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** 5.8 (+) (Short-term increase)
*   **Expected Return (%):** 2.2%

**Analysis:**

*   The MRI suggests a "Medium Investment" recommendation.
*   The RSI (44.40) indicates the stock is neither overbought nor oversold.
*   The positive PPO (0.36) suggests a slight bullish trend.
*   The hybrid signal points towards a "Buy" recommendation, even with a 0% cash position, which suggests aggressive investment.
*   The 20-day relative divergence change suggests a short-term increase in performance relative to the comparison index.
*   The expected return of 2.2% is relatively modest.

**4. Recent News & Significant Events**

*   **JPMorgan Cuts Price Target:** Suggests some concerns among analysts.
*   **Stock Sinks as Market Gains:** Highlights recent underperformance.
*   **Cramer's Favorite Portfolio Stock:** Positive coverage from a well-known commentator.
*   **Analyst Downgrade:** Negative signal impacting the stock price.
*   **Buy PG Stock Over Colgate-Palmolive?:** A comparative analysis suggesting potential value in PG over a competitor.
*   **Hit 2-Year Low:** Highlights recent price weakness.

**Analysis:** Recent news is mixed, with some positive endorsements, but also downgrades, price target cuts, and concerns about underperformance. This suggests a period of uncertainty and re-evaluation for PG.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean 1.92)
*   **Target Price:** 169.18 (Avg)
*   **Recent Rating Changes:** Not specified in provided Data

**Analysis:** Despite the mixed news, the overall analyst consensus remains "Buy" with a significant upside potential based on the average target price.

**5. Recent Earnings Analysis**

| 날짜       | EPS  | 매출     |
|------------|------|----------|
| 2025-10-24 | 2    | 22.39 B$ |
| 2025-04-24 | 1.58 | 19.78 B$ |
| 2025-01-22 | 1.94 | 21.88 B$ |
| 2024-10-18 | 1.65 | 21.74 B$ |
| 2025-10-24 | 1.65 | 21.74 B$ |

**Analysis:**

*   Revenue has fluctuated, but generally remained strong.
*   EPS has also varied, with the latest figure showing improvement.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $22.39B   | 51.37%        |
| 2025-06-30   | $20.89B   | 49.11%        |
| 2025-03-31   | $19.78B   | 50.98%        |
| 2024-12-31   | $21.88B   | 52.39%        |
| 2024-09-30   | $21.74B   | 52.06%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE    |
|--------------|-----------|--------|
| 2025-09-30   | $53.27B   | 8.92%  |
| 2025-06-30   | $52.01B   | 6.95%  |
| 2025-03-31   | $52.27B   | 7.21%  |
| 2024-12-31   | $51.17B   | 9.05%  |
| 2024-09-30   | $51.84B   | 7.64%  |

**Analysis:**

*   **Revenue:** Relatively stable over the past five quarters, with a slight uptrend.
*   **Profit Margin:** Strong and consistent, indicating good cost management.
*   **Equity:** Gradually increasing, indicating growth in the company's net worth.
*   **ROE (Return on Equity):** Fluctuates but remains at a reasonable level, showing profitability relative to shareholder equity.

**7. Comprehensive Analysis**

Procter & Gamble (PG) is a stable company with consistent revenue and profitability. However, it has significantly underperformed the S&P 500 in recent years.

*   **Negatives:** The divergence from the S&P 500 is substantial, indicating the stock has not kept pace with broader market gains. The recent news flow is mixed, including analyst downgrades and concerns about underperformance. Recent Alpha and CAGR figures are poor. The maximum drawdown has been increasing.
*   **Positives:** P&G's financial health appears solid, with robust profit margins and increasing equity. Analysts still maintain a "Buy" consensus with a significant upside target price. Recent SMA trends and relative divergence suggest potential for short-term gains. The MRI is at a level which recommends medium investment.
*   **Overall:** The investment recommendation depends on your risk tolerance and investment horizon. PG could be considered a potentially undervalued stock (given analyst targets) with decent long-term stability. However, recent underperformance relative to broader market indices is an important consideration. The current Hybrid Signal aggressive buy recommendation should be taken with caution considering the other analyses.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.